Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis

20132,803 citationsJournal Articlebronze Open Access

Authors

Brian G. Feagan · Western University

Paul Rutgeerts

Bruce E. Sands · Icahn School of Medicine at Mount Sinai

Stephen B. Hanauer · University of Chicago

Jean‐Frédéric Colombel · Centre Hospitalier Universitaire de Lille

William J. Sandborn · University of California San Diego

Gert Van Assche

Jeffrey Axler

Abstract

Ustekinumab was more effective than placebo for inducing and maintaining remission in patients with moderate-to-severe ulcerative colitis. (Funded by Janssen Research and Development; UNIFI ClinicalTrials.gov number, NCT02407236.).

Topics & Keywords

Inflammatory Bowel Disease Microscopic Colitis Celiac Disease Research and Management

UN Sustainable Development Goals

Gender equality

Publication Details

Published in: New England Journal of Medicine

Volume 369, Issue 8, pp. 699-710

DOI: 10.1056/nejmoa1215734

Field-Weighted Citation Impact: 103.33